Economic Considerations in Alzheimer's Disease

@article{Meek1998EconomicCI,
  title={Economic Considerations in Alzheimer's Disease},
  author={P. Meek and E. McKeithan and G. Schumock},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={1998},
  volume={18}
}
Alzheimer's disease (AD) is the third most expensive disease in the United States, costing society approximately $100 billion each year. It is one of the most prevalent illnesses in the elderly population, and with the aging of society, will become even more significant. Costs associated with AD include direct medical costs such as nursing home care, direct nonmedical costs such as in‐home day care, and indirect costs such as lost patient and caregiver productivity. Medical treatment may have… Expand
Economic considerations in the management of Alzheimer’s disease
The pharmacoeconomics of Alzheimer's disease.
  • H. Fillit
  • Medicine
  • The American journal of managed care
  • 2000
The Impact of Symptom Severity on the Cost of Alzheimer's Disease
Managed care decisions in Alzheimer's disease.
  • H. Fillit
  • Medicine
  • The American journal of managed care
  • 2000
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
The economic burden of Alzheimer's disease care.
Estimated prevalence of Alzheimer's disease in the United States.
  • D. Evans
  • Medicine
  • The Milbank quarterly
  • 1990
The US economic and social costs of Alzheimer's disease revisited.
Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
...
1
2
...